Wegovy and Ozempic are two weight loss medications that have gained attention for their effectiveness in reducing body weight. However, they have different origins, mechanisms of action, and intended uses.

Wegovy, developed by Novo Nordisk, is a prescription medication approved by the US FDA in 2021 for chronic weight management in adults with obesity ([1], drugpatentwatch.com). It is a semaglutide injectable pen, available in a 2.25 mg dose, administered once weekly. Wegovy works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1), which regulates appetite and metabolism ([2]).

On the other hand, Ozempic, also developed by Novo Nordisk, is primarily used to manage blood sugar levels in adults with type 2 diabetes ([3], drugpatentwatch.com). Ozempic is a semaglutide injectable solution, available in various doses, including 0.5 mg, 1 mg, and 1.5 mg per day ([4]). Ozempic, like Wegovy, mimics the actions of GLP-1, but with a narrower focus on glucose regulation.

The main differences between Wegovy and Ozempic lie in their intended uses and dosing regimens. Wegovy is specifically designed for weight loss in obese adults, whereas Ozempic is used to manage blood sugar levels. Wegovy's once-weekly 2.25 mg dose is significantly higher than Ozempic's daily doses ([5]).

Sources:

[1] https://drugpatentwatch.com/2021/12/09/novo-nordisk-secures-fast-track-designation-for-semaglutide-in-new-indication/
[2] https://www.novo-pharma.com/products-and-services/weight-management/we-govy/
[3] https://www.novo-pharma.com/products-and-services/diabetes-management/ozempic/
[4] https://www.drugs.com/ozempic.html
[5] https://www.novo-pharma.com/products-and-services/weight-management/we-govy/